Profile data is unavailable for this security.
About the company
Shield Therapeutics plc is a United Kingdom-based commercial stage specialty pharmaceutical company. The Company specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.
- Revenue in GBP (TTM)1.95m
- Net income in GBP-13.04m
- Incorporated2015
- Employees16.00
- LocationShield Therapeutics PLC3rd FlBaltic Business Quarters, AbboGATESHEAD NE8 3DUnited KingdomGBR
- Phone+44 191 511 8500
- Websitehttps://www.shieldtherapeutics.com/